IND regs offer more ways to expand access - and to charge patients for it
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs. A companion reg also gives companies more options for changing patients for experimental products - if they are willing to open their books up to FDA (1"The Pink Sheet," Aug. 17, 2009)
You may also be interested in...
FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs
Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.